KRAS and cancer: Future clinical studies, utilizing combination studies of mutant KRAS inhibitors with inhibitors of these adaptive response mechanisms [35,36,37,38,39], will hold potential for the development of a potent and effective therapy for cancers harboring KRAS mutations.